Stryker Corp's stock rose by 4.29%, reaching a 20-day high, amid positive market conditions with the Nasdaq-100 up 0.89% and the S&P 500 up 0.62%.
The increase in Stryker's stock price is attributed to an upgrade by Raymond James analyst Jayson Bedford, who raised the rating to 'outperform' with a price target of $418. This upgrade reflects confidence in Stryker's sustained growth, as the company has achieved over 10% organic revenue growth for five consecutive years, despite a challenging previous year. Analysts believe that the current P/E ratio of approximately 23 times is undervalued compared to the company's growth potential, suggesting a positive outlook for the stock.
This analyst upgrade has generated optimism among investors, indicating that Stryker's stock may continue to recover as the market recognizes its growth potential and improved valuation.
Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 430.32 USD with a low forecast of 390.00 USD and a high forecast of 465.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is 430.32 USD with a low forecast of 390.00 USD and a high forecast of 465.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 357.830
Low
390.00
Averages
430.32
High
465.00
Current: 357.830
Low
390.00
Averages
430.32
High
465.00
TD Cowen
Buy
to
Hold
downgrade
$387
2026-01-26
New
Reason
TD Cowen
Price Target
$387
AI Analysis
2026-01-26
New
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded Stryker to Hold from Buy with a $387 price target as he took over coverage. While stating that "there's a lot we like about the story today and through decade-end," the firm thinks a "beat/raise precedent" is well understood and reflected in valuation. The firm would like to isolate underappreciated themes that can provide "unanticipated" upside to get more positive on the shares, the analyst tells investors.
Goldman Sachs
Neutral
downgrade
$418 -> $399
2026-01-09
Reason
Goldman Sachs
Price Target
$418 -> $399
2026-01-09
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on Stryker to $399 from $418 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SYK
Unlock Now
Bernstein
Lee Hambright
Outperform
maintain
$450 -> $465
2026-01-09
Reason
Bernstein
Lee Hambright
Price Target
$450 -> $465
2026-01-09
maintain
Outperform
Reason
Bernstein analyst Lee Hambright raised the firm's price target on Stryker to $465 from $450 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Raymond James
Market Perform
to
Outperform
upgrade
$418
2026-01-06
Reason
Raymond James
Price Target
$418
2026-01-06
upgrade
Market Perform
to
Outperform
Reason
Raymond James upgraded Stryker to Outperform from Market Perform with a $418 price target. The company has been one of the "highest quality compounders" in medical technology for the last five years, but the stock's forward multiple compressed in 2025, as estimates trended higher, the analyst tells investors in a research note. Raymond James says this does not make sense. Stryker's current valuation represents an attractive entry point, the firm contends.
About SYK
Stryker Corporation is a medical technology company. The Company offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics products primarily include implants used in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. The Company also offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
